Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

Phase 2 Completed 320 enrolled Jennifer Keiser Public Health Laboratory Ivo de Carneri · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy and safety of emodepside to that of albendazole (Zentel®) in participants aged 12-60, inclusive, infected with hookworm.

Timeline

Start: 2022-09-16
Primary completion: 2023-04-11
Completion: 2023-04-11

Outcome

Met primary endpoint

paper Emodepside demonstrated superiority, with an observed cure rate against hookworm of 96·6%, which was significantly higher compared with albendazole PMID 39153818 ↗

Publications

Taylor L, Ahmada AA, Ali MS, Ali SM, Hattendorf J, Mohammed IS, Keiser J. Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial. Lancet. 2024 Aug 17;404(10453):683-691. doi: 10.1016/S0140-6736(24)01403-X.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Albendazole	Small molecule	400 mg	—
Subject	Emodepside	Small molecule	30 mg	—